Today, UCB issued the following statement from Jeffrey Stark, M.D., Head of U.S. Medical Immunology, on the recent update by the ICD-10 Coordination and Maintenance Committee to endorse the creation of a new sub-category (M45.A) for non-radiographic axial spondyloarthritis (nr-axSpA). 

The journey of developing inclusive and innovative solutions to our clinical trials approach began several years ago at UCB, and we continue to progress towards this goal every day, laser-focused on improving representation in clinical studies. This Clinical Trials Day, we’re highlighting the work UCB employees are doing to address health inequities in clinical trials through digital business transformation, and approaches like decentralized clinical trials, leveraging real-world evidence, and personalized tools to enhance the patient experience.    

As we each continue to adapt to the changes, challenges, and opportunities of the past year, we aim to foster a working environment where our employees are happy, healthy, and thriving. To do this, UCB prioritizes enabling the right conditions – in the workplace or at home – for our colleagues to be their best selves. This Mental Health Awareness Month, learn how we’re putting the mental wellness of our colleagues, their families, and patients at the center of our focus.

Our Community Health Fund launched a first call for projects last year to support vulnerable people impacted by the pandemic. Our second call will focus on organizations and projects which have a positive impact on the mental health of young people. Apply now to make a difference. 

Every three seconds a fragility fracture occurs. But when someone has a bone break it may not just be a part of getting older. Often, it is due to the underlying condition of osteoporosis. This Osteoporosis Awareness Month, learn how the UCB Bone Health Team works with healthcare partners, including hospitals, integrated delivery systems, and community partners, to create a better system for osteoporosis care driven by what patients want and need.

As stakeholders emerge from the pandemic with newfound insights about what constitutes high-value care, it appears that more—not less—disruption may be needed. Read more from Head of U.S. Corporate Affairs, Patty Fritz, on how UCB is extending our focus beyond the medicine to deliver value for patients.

Our recent launch of dynamic targeting in the U.S. is providing UCB a better grasp of physician needs, which can lead to better healthcare outcomes. This is a key building block in UCB’s digital transformation journey providing a proven blueprint and lessons learned to continue innovating now and in the future. This initiative was recognized as the Most Valuable Data and Insights Initiative at the Reuters Pharma Awards USA 2020. Read how UCB has improved efficiencies for our teams and helped evolve the field experience. The article was originally published by ZS.

Congratulations to Anita Moser, Head of U.S. Neurology Assets and Optimization, and Erica Puntel, U.S. Neurology and Global Digital Business Transformation Communications Lead, for their recognition as Healthcare Businesswomen's Association (HBA) Rising Stars for 2021.

UCB is passionate about transforming the lives of people living with severe diseases and uncovering the intersections of scientific understanding and patient needs. This May, we are honoring Arthritis Awareness Month and Spondyloarthritis Awareness Month by exploring the impacts of different kinds of arthritis on patients. Learn more about psoriatic arthritis, rheumatoid arthritis, and non-radiographic axial spondyloarthritis, their prevalence, and how individuals living with these diseases are impacted.

UCB is proud to be one of 26 members launching the IP PACT and we invite you to learn more about the commitments we are making to ensure our approach to IP delivers value for society, patients, and UCB.